INTRODUCTION
============

Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis, which was first reported by Dalmau in 2007,[@B1] is the most common type of autoimmune encephalitis (AE), with a mortality rate of 8--10%.[@B1] It usually affects children and young women with a clinical spectrum that includes acute or subacute psychiatric symptoms, cognitive disorders, epilepsy, decreased consciousness, and autonomic dysfunction, with or without teratoma.[@B2] The confirmed main mechanism is dysfunction of NMDARs due to immunoglobulin G (IgG)-mediated internalization that probably occurs throughout the brain.[@B3]

Anti-NMDAR encephalitis is chiefly mediated by humoral immunity, and so its management focuses on immunotherapy and the detection and removal of tumors.[@B4] The first-line treatments include steroids, intravenous immunoglobulin (IVIg), or plasma exchange either alone or in combination. A second-line immunotherapy such as rituximab, cyclophosphamide, or bortezomib can also be applied.[@B5]

The so-called NEOS score was recently proposed for predicting the 1-year functional status in patients with anti-NMDA receptor encephalitis.[@B6] This score includes admission to an intensive-care unit (ICU), treatment delay \>4 weeks, lack of clinical improvement within 4 weeks, abnormal MRI findings, and a CSF white blood cell (WBC) count \>20 cells/µL. A systematic review[@B7] of the prognosis in AE found that altered consciousness, ICU admission, and no use of immunotherapy were associated with a poor prognosis in anti-NMDAR encephalitis. A Korean study found that a high albumin level is a predictor of a favorable response to immunotherapy in AE.[@B8] Our team has recently reported that the neutrophil-to-lymphocyte ratio in peripheral blood (NLR) is a practical and reliable biomarker for monitoring the disease progression in patients with AE.[@B9]

All of the above-mentioned studies considered possible predictors of the long-term prognosis in patients with AE, but no previous study has focused on the therapeutic response to first-line treatments in patients with anti-NMDAR encephalitis. A large-scale observational cohort study found that 47% of patients did not improve following first-line treatments and so needed to receive a second-line immunotherapy that included rituximab or cyclophosphamide alone or in combination.[@B5] It is essential to identify patients who respond poorly to first-line treatments so that second-line immunotherapy can be administered in a timely manner.

In this study we summarized the clinical features of patients with anti-NMDAR encephalitis who did not exhibit clinical improvement after receiving first-line treatments, with the aim of identifying the factors influencing the response to first-line treatments.

METHODS
=======

Patient eligibility and grouping
--------------------------------

This retrospective study enrolled 29 patients who were diagnosed as anti-NMDAR encephalitis in the Department of Neurology of Shandong Provincial Hospital Affiliated to Shandong University between January 1, 2015, and June 30, 2018. The diagnostic criteria were as follows: i) the rapid onset (less than 3 months) of at least one of the following six major groups of symptoms: 1) abnormal (psychiatric) behavior or cognitive dysfunction, 2) speech dysfunction (pressured speech, verbal reduction, or mutism), 3) seizures, 4) movement disorder, dyskinesias, or rigidity/abnormal postures, 5) decreased level of consciousness, 6) autonomic dysfunction, or central hypoventilation; ii) positivity for IgG anti-NMDAR antibodies; and iii) reasonable exclusion of other disorders.

Patients included in the remission group had responded to first-line treatments when methylprednisolone was reduced to oral intake (60 mg) and IVIg was finished within one round. We defined the nonremission group as the absence of a sustained improvement or the modified Rankin scale (mRS) score remaining at 4 or higher.[@B5]

The study was approved by the Research Ethics Committee of Shandong Provincial Hospital Affiliated to Shandong University (IRB No. LCYJ: NO.2017-015).

Data collection
---------------

The clinical data of the 29 enrolled patients that were collected retrospectively included sex, age, clinical symptoms, presence of teratoma or other tumors, cranial MRI findings, EEG, antibody titers in serum and CSF (used to classify the samples as negative, weak positive, positive, and strong positive), pressure in a lumbar puncture, and number of nucleated cells and level of protein in CSF (all of the CSF parameters were obtained before first-line treatments). The symptoms were categorized into six groups based on the above-mentioned diagnostic criteria.[@B10] and all occurred before treatment or during the course of first-line treatments. Malignancy investigations included CT of the abdomen and chest as well as ultrasonography of the reproductive organs. Whole-body PET with whole-body CT was performed when necessary.

Other routine blood examinations focused on the following indicators: NLR, liver function test \[aspartate aminotransferase (AST), alanine aminotransferase, and glutamyltranspeptidase\], uric acid (UA), D-dimer, fibrinogen, creatinine, thyroid function, homocysteine, and cystatin C (CysC).

All of the patients enrolled in this study received the following standard first-line treatments: high-dose methylprednisolone (initial dose of 1,000 mg with halving every 3 days until it was reduced to 60 mg orally) plus IVIg (0.4 g/kg/day for 5 days). No plasma exchange was performed because the hospital conditions did not allow this. All of the cancer patients received tumor resection. All of the patients were routinely given mycophenolate mofetil (MMF) as a long-term immunotherapy to prevent recurrence when methylprednisolone was reduced to oral intake. The response to first-line treatments was evaluated before applying MMF therapy. The subsequently applied major second-line treatments included rituximab and bortezomib. The severity of the disease and outcome were assessed using the mRS score. After discharge, the outcome was evaluated during a clinical visit to the neurologist or in a telephone follow-up.

Statistical analyses
--------------------

SPSS software (version 22.0, IBM Corporation, Armonk, NY, USA) was used for all statistical analyses. All continuous variables that conformed to a normal distribution are expressed as mean±SD values, while the other continuous variables are expressed as median and range values. Student\'s *t* test was used to analyze intergroup data that conformed to a normal distribution and had a heterogeneous variance; otherwise the Mann-Whitney U test was used. Fisher\'s exact test was used to analyze categorical variables. Pearson\'s correlation was applied to the levels of serum albumin and mRS scores. Probability values of *p*\<0.05 were assumed to indicate statistically significant differences.

RESULTS
=======

Clinical characteristics
------------------------

The demographic and clinical manifestations are summarized in [Table 1](#T1){ref-type="table"}. The 29 included patients comprised 11 males (37.93%) and 18 females (62.07%). The application of the grouping criteria resulted in 18 patients (62.07%) in the remission group and 11 patients (37.93%) in the nonremission group. The ages of the patients ranged between 13 and 54 years (median 34 years), and did not differ significantly between the two groups. Five female patients had ovarian teratoma, and in all cases the ovarian lesion was removed after admission. No other tumors were found. Compared with the remission group, patients in the nonremission group had more symptoms and a higher proportion of them exhibited involuntary movements, decreased consciousness, and central hypoventilation. Regarding accompanying symptoms, we found no differences in prodromal symptoms such as fever and headache between the two groups; however, the proportion of patients with lung infection and hypoalbuminemia was higher in the nonremission group. Five patients had been in an ICU for supportive treatment, all of whom were in the nonremission group.

Ancillary examinations
----------------------

The initial CSF, antibody titers, brain MRI, EEG, and laboratory findings are presented in [Table 2](#T2){ref-type="table"}. Twelve (41.38%) of the 29 patients exhibited normal brain MRI findings. The abnormal MRI lesions in T2-weighted or FLAIR images were distributed as follows: eight patients with increased signals in the medial temporal lobe or hippocampus, five patients with increased signals in the cerebral cortex, three patients with increased signals in the basal ganglia, and one patient with contrast enhancement of the optic nerve. The distribution of intracranial lesions did not differ between the two groups.

The EEG findings were abnormal in 16 (88.89%) of the 18 patients for whom EEG information was available. Most EEGs were collected during the seizure interval, and almost all of the patients had bilateral or unilateral generalized slow waves, while one patient exhibited diffuse beta activities and no epileptiform discharges were found.

The intracranial pressure was higher than 180 mm H~2~O in nine patients, most of whom were in the nonremission group (*p*=0.048). No significant difference was found in leukocyte and protein levels in CSF. Eight patients were negative for NMDAR antibody in serum but none of the 29 patients showed negativity in CSF. The distribution of the antibody titers in all of the patients is presented in [Table 2](#T2){ref-type="table"}; there were no differences between the two groups.

We calculated the NLR before and after first-line treatments in both groups of patients. The NLR was lower in the remission group than the nonremission group before and after the first-line treatments (*p*=0.011 and *p*=0.003, respectively) ([Fig. 1](#F1){ref-type="fig"}). The albumin levels after the first-line treatments were lower in the nonremission group than the remission group, and the changes in these levels were associated with changes in the mRS scores ([Fig. 2](#F2){ref-type="fig"}). A lack of data meant that information on liver enzyme indicators, UA, D-dimer, fibrinogen, creatinine, homocysteine, CysC, and thyroid function was only collected before the first-line treatments. For the remaining collected laboratory indicators, only AST and fibrinogen were significantly elevated in the nonremission group.

Follow-up treatments and prognosis
----------------------------------

Six patients (54.55%) in the nonremission group received low-dose rituximab, two of whom also received bortezomib. Four patients did not receive second-line immunotherapy due to economic reasons or intolerance. All of them were still in a state of severe neurological deficit at discharge. Only one patient (3.45%) died, which was due to multiple- organ failure. At a 1-year follow-up, only two patients did not reach the evaluation standard for a favorable outcome (mRS score \<3). Four patients had relapsed at the follow-up, two of whom were in the nonremission group and had not received second-line treatments such as rituximab.

DISCUSSION
==========

Anti-NMDAR encephalitis is a type of autoimmune disease that can be reversed by early active treatment. This study analyzed the differences between anti-NMDAR-encephalitis patients in remission and nonremission groups after they received first-line treatments, and identified the possible factors affecting the responses to first-line treatments.

According to previous researches, anti-NMDAR encephalitis is mainly found in young females.[@B1] In the present study, the median age was 34 years and 62.07% of the patients were female, with no sex or age difference between the two groups. In the largest observational cohort study so far,[@B5] 38% of the anti-NMDAR-encephalitis patients had tumors, 94% of which were ovarian teratomas. However, in our study only five patients (17.24%) had ovarian teratomas, which might have been due to the small number of included patients.

We found that the presence of a larger number of symptoms is associated with a lower sensitivity to first-line treatments (*p*\<0.01). Abnormal (psychiatric) behavior and cognitive dysfunction are common symptoms in anti-NMDAR encephalitis.[@B10] This was also true in our study, but we did not find differences in the incidence of these features between the two groups. Seizures are another common symptom of anti-NMDAR encephalitis. Although the incidence rates of epilepsy and status epilepticus did not differ between the two groups, only one of the four patients with status epilepticus responded to the first-line treatments. We therefore speculate that status epilepticus affects the response to first-line treatments in patients with anti-NMDAR encephalitis. Wang et al.[@B11] found that children with anti-NMDAR encephalitis who received both first-line and second-line immunotherapy had a higher incidence of autonomic instability, decreased consciousness, and pediatric ICU stay. An observational study of 111 patients[@B12] found that a higher proportion of those in the severe group exhibited involuntary movements, disturbance of consciousness, autonomic dysfunction, and central hypoventilation. It was recently proposed that ICU admission, treatment delay \>4 weeks, lack of clinical improvement within 4 weeks, and the presence of movement disorder and central hypoventilation were associated with the 1-year functional status in AE.[@B6] Our research findings are basically consistent with those findings, but we also found that the time from onset to diagnosis did not differ between the two groups. A previous study indicated that orofacial-lingual dyskinesia, tremor, and dystonia were the common types of involuntary movements in anti-NMDAR encephalitis.[@B13] Histological data have revealed the distribution of NMDAR in the brainstem, but the cause of central hypoventilation in patients with anti-NMDAR encephalitis remains unclear---it may be associated with secondary brainstem lesions or a functional neurotransmitter imbalance.[@B14][@B15] Severe patients exhibiting decreased consciousness and central hypoventilation generally require artificial-airway- and ventilator-assisted breathing, while involuntary movements of the face and dystonia may have a considerable impact on airway management.[@B12]

A Korean study found that a high albumin level is a predictor of a favorable response to immunotherapy in AE.[@B8] Our study has confirmed this view from another perspective, by observing that hypoalbuminemia was more likely to occur in the nonremission group, and a significant correlation being found between a decrease in the albumin level and the changes in mRS scores (*r*=−0.399, *p*=0.032). A low albumin level is also associated with a poor prognosis in Guillain-Barré syndrome.[@B16] The serum albumin levels might be an indicator of IVIg pharmacokinetics, which would result in the serum albumin level indirectly representing the recycling capacity of the neonatal Fc receptor as a target of IVIg. Similarly, a combined lung infection and admission to an ICU are possible indicators of an NMDAR-encephalitis patient not responding to first-line treatments, which are reportedly risk factors for mortality.[@B17]

Dalmau et al.[@B2][@B18] described that the distribution of intracranial lesions in patients with anti-NMDAR encephalitis was not specific, with them possibly being seen in the hippocampi, cerebellar or cerebral cortex, frontobasal and insular regions, basal ganglia, brainstem and, infrequently, the spinal cord. Those authors found that 50% of patients had normal brain MRI findings, and this is consistent with our results. As for EEGs, a study reported on in 2018[@B19] found that the sensitivity of an abnormal EEG was high and that the first EEG recording was predictive of the final clinical outcome. The small amount of available data prevents us from discussing the differences in EEGs between the two groups in detail.

In a study of CSF findings in anti-NMDAR encephalitis, Wang et al.[@B20] found that 39.5% of their patients exhibited increased CSF pressures, 58.1% had CSF pleocytosis, and 18.6% had elevated CSF protein, but there was no relationship between changes in CSF findings and clinical outcomes. Our results are consistent with these findings, although we found that increased CSF pressure was related to poor responses to first-line treatments. However, Balu et al.[@B6] found that both elevated CSF WBC count and CSF protein were associated with the 1-year outcome of AE. We found that 8 of our 29 patients were negative for NMDAR antibody in serum and none of them were negative in CSF, which verified the view of Wang et al.[@B20] that detecting NMDAR antibodies is more sensitive in CSF than in serum. A previous study[@B21] found that CSF and serum titers were higher in anti-NMDAR-encephalitis patients with poor outcomes than in those with good outcomes, whereas we found no differences between the remission and nonremission groups.

As a marker of systemic inflammation, the NLR is more reliable and stable than the WBC count for reflecting inflammatory responses. The NLR might be a useful marker for assessing the disease activity in neuromyelitis optica spectrum disorder, multiple sclerosis (MS), and systemic lupus erythematosus patients.[@B22][@B23][@B24] Our team has recently reported that the NLR is a practical and reliable biomarker for monitoring disease progression in patients with AE.[@B9] In the present study, the NLR was higher in the nonremission group before and after treatment, which may be attributed to the severe inflammatory response and the high probability of pulmonary infection in severe patients. Among the indicators of liver function and blood biochemistry, only AST was elevated in the nonremission group. We cannot conclude that patients with abnormal liver function have a reduced sensitivity to first-line treatments, since no significant difference in other liver function indicators. This might be attributable to drugs such as methylprednisolone being metabolized mainly in the liver. Previous studies[@B25][@B26] have shown that the serum levels of UA and CysC were reduced in the acute phase of patients with anti-NMDAR encephalitis and were associated with the disease severity. However, we did not find differences in these parameters between the two groups in our study. We also found that the fibrinogen level was high in the nonremission group and that the patient who died presented with severe coagulopathy that eventually developed into diffuse intravascular coagulation. Fibrinogen is reportedly elevated in patients with MS and neuromyelitis optica.[@B27] but the relationship between fibrinogen and anti-NMDAR encephalitis is unclear.

Six (54.55%) of the patients in the nonremission group received second-line immunotherapy, which was consistent with the cohort study of Titulaer et al.[@B5] Only one patient died, which was due to multiple- organ failure. The mortality rate was lower than that reported in the literature (5--7%).

This study was subject to some limitations, including the small number of patients and missing data such as for long-term EEG monitoring and laboratory indicators after the treatments. The retrospective design meant that some clinical data were incomplete. Prospective studies with larger cohorts are therefore needed to validate the findings reported here.

In conclusion, this study found that anti-NMDAR-encephalitis patients with more symptoms---especially involuntary movements, disturbance of consciousness, central hypoventilation, and accompanying hypoalbuminemia and pulmonary infection---may exhibit poor responses to first-line treatments. Positive second-line immunotherapy needs to be considered. Admission to an ICU, increased CSF pressure, and increased NLR are possible factors affecting the response to first-line treatments.
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###### Demographics and clinical manifestations of patients with anti-NMDAR encephalitis in the remission and nonremission groups

![](jcn-15-369-i001)

                                                              Total (*n*=29)   Remission (*n*=18)   Nonremission (*n*=11)   *p*
  ----------------------------------------------------------- ---------------- -------------------- ----------------------- ---------
  Age, years                                                  34 \[13--54\]    35 \[14--53\]        34 \[13--54\]           0.829
  Sex                                                                                                                       
   Male                                                       11 (37.93)       6 (33.33)            5 (45.45)               0.696
   Female                                                     18 (62.07)       12 (66.67)           6 (54.55)               
  Interval to a definitive diagnosis, days                    20 \[10--90\]    27 \[10--90\]        20 \[10--60\]           0.512
  Tumor                                                                                                                     
   Ovarian teratoma                                           5 (17.24)        3 (16.67)            2 (18.18)               1.000
   None                                                       24 (82.76)       15 (83.33)           9 (81.82)               
  Accompanying symptoms                                                                                                     
   Fever                                                      20 (68.97)       11 (61.11)           9 (81.82)               1.000
   Headache                                                   18 (62.07)       10 (55.56)           8 (72.73)               0.449
   Hypoalbuminemia                                            11 (37.93)       3 (16.67)            8 (72.73)               0.005
   Lung infection                                             12 (41.38)       3 (16.67)            9 (81.82)               0.001
  Number of six major symptoms                                4 \[1--6\]       3 \[1--5\]           5 \[2--6\]              \<0.001
   Mental behavior disorder or cognitive impairment           26 (89.66)       16 (88.9)            10 (90.91)              1.000
   Epileptic seizure                                          25 (86.21)       16 (88.89)           9 (81.82)               0.622
   Involuntary movement                                       10 (34.83)       3 (16.67)            7 (63.64)               0.017
   Decreased consciousness                                    16 (55.17)       6 (33.33)            10 (90.91)              0.006
   Speech disturbance                                         11 (37.93)       7 (38.89)            4 (36.34)               1.000
   Autonomic nervous dysfunction or central hypoventilation   8 (27.59)        1 (5.56)             7 (63.64)               0.001
  Status epilepticus                                          4 (13.79)        1 (5.56)             3 (27.27)               0.139
  Admission to an intensive-care unit                         5 (17.24)        0 (0)                5 (45.45)               0.004

Data are median \[range\] or *n* (%) values.

NMDAR: N-methyl-D-aspartate receptor.

###### Findings of the ancillary examinations in patients with anti-NMDAR encephalitis in the two groups
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                                                Total (*n*=29)            Remission (*n*=18)       Nonremission (*n*=11)    *p*
  --------------------------------------------- ------------------------- ------------------------ ------------------------ -------
  MRI findings                                                                                                              
   Normal                                       12 (41.38)                9 (33.33)                3 (27.27)                
   Temporal lobe and hippocampus                8 (27.59)                 5 (27.78)                3 (27.27)                
   Cortical lesion                              5 (17.24)                 2 (11.11)                3 (27.27)                
   Basal ganglion                               3 (10.34)                 2 (11.11)                1 (9.10)                 
   Others                                       1                         0                        1 (9.10)                 
  Abnormal EEG (information from 18 patients)   16                        9                        7                        
  CSF findings                                                                                                              
   Increased intracranial pressure              9 (31.03)                 3 (16.67)                6 (54.55)                0.048
   CSF WBC count (×10^6^)                       22 \[2--286\]             21 \[2--286\]            25 \[2--180\]            0.498
   CSF protein, g/L                             0.28 \[0.12--0.94\]       0.30 \[0.12--0.94\]      0.28 \[0.21--0.59\]      0.491
  CSF NMDAR antibody titers                                                                                                 0.643
   Negative                                     0                         0                        0                        
   Weak positive                                4 (13.79)                 3 (16.67)                1 (9.10)                 
   Positive                                     7 (24.14)                 5 (27.78)                2 (18.18)                
   Strong positive                              18 (62.07)                10 (55.56)               8 (72.73)                
  Serum NMDAR antibody titers                                                                                               0.247
   Negative                                     8 (27.59)                 4 (22.22)                4 (36.36)                
   Weak positive                                13 (44.83)                10 (55.56)               3 (27.27)                
   Positive                                     4 (13.79)                 3 (16.67)                1 (9.10)                 
   Strong positive                              4 (13.79)                 1 (5.56)                 3 (27.27)                
  NLR~1~                                        2.66 \[1.32--9.86\]       2.39 \[1.32--4.43\]      4.10 \[1.64--9.86\]      0.011
  NLR~2~                                        3.07 \[1.71--19.56\]      2.62 \[1.71--3.86\]      4.14 \[1.94--19.56\]     0.003
  Albumin~1~                                    42.20 \[30.50--47.30\]    41.80 \[35.40--45.30\]   42.30 \[30.50--47.30\]   0.431
  Albumin~2~                                    36.30 \[16.90--43.90\]    38.50 \[32.60--43.20\]   32.70 \[16.90--43.90\]   0.012
  AST                                           20.00 \[12.00--93.00\]    17.50 \[12.00--66.00\]   31.00 \[14.00--93.00\]   0.030
  ALT                                           19.00 \[8.00--86.00\]     16.50 \[8.00--86.00\]    22.00 \[10.00--80.00\]   0.368
  GGT                                           22.00 \[12.00--95.00)\]   18.50 \[12.00--46.00\]   22.00 \[15.00--95.00\]   0.148
  Homocysteine                                  11.70 \[4.60--97.60\]     11.20 \[4.6--97.60\]     12.30 \[4.600--25.30\]   0.904
  Uric acid                                     258±118                   246±86                   276±157                  0.525
  CysC                                          0.79±0.24                 0.85±0.25                0.70±0.19                0.094
  Creatinine                                    54.26±12.56               54.91±13.04              53.37±12.46              0.763
  FT3                                           3.84±0.88                 3.99±0.71                3.58±1.09                0.296
  FT4                                           16.64±3.53                16.41±4.17               17.00±2.33               0.722
  TSH                                           1.34±1.09                 1.54±1.16                1.01±0.92                0.292
  D-dimer                                       0.59 \[0.15--3.66\]       0.36 \[0.15--1.80\]      0.69 \[0.19--3.66\]      0.052
  Fibrinogen                                    3.26±0.86                 2.99±0.76                3.80±0.84                0.026

Data are median \[range\], mean±SD, or *n* (%) values.

Albumin~1~: albumin level before first-line treatments, Albumin~2~: albumin level after first-line treatments, ALT: alanine aminotransferase, AST: aspartate aminotransferase, CysC: cystatin C, FT3: free tri-iodothyronine, FT4: serum free thyroxin, GGT: glutamyltranspeptidase, NLR: neutrophil-to-lymphocyte ratio in peripheral blood, NLR~1~: NLR before first-line treatments, NLR~2~: NLR after first-line treatments, NMDAR: N-methyl-D-aspartate receptor, TSH: thyroid-stimulating hormone, WBC: white blood cell.
